Prevalence and Characteristics of Transthyretin Amyloidosis in Patients With Left Ventricular Hypertrophy of Unknown Etiology
NCT ID: NCT03842163
Last Updated: 2024-02-12
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
812 participants
OBSERVATIONAL
2018-07-09
2022-06-08
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Radioisotope Scintigraphy to Establish Incidence of Cardiac Amyloidosis Among Patients With Otherwise Unexplained Cardiac Disease
NCT03098901
Transthyretin Cardiac Amyloidosis in HFpEF
NCT03414632
Prevalence of Transthyretin Amyloidosis in Hypertrophic Cardiomyopathy
NCT01623245
Prevalence of Transthyretin Cardiac Amyloidosis in Clinically Significant Aortic Stenosis
NCT04899180
The Regional Scintigraphic DPD Uptake in Cardiac Transthyretin Amyloidosis.
NCT05814380
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients with LVH of unknown etiology
Diagnosis of TTR amyloidosis cardiomyopathy
Diagnosis of TTR amyloidosis cardiomyopathy with scintigraphy
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Diagnosis of TTR amyloidosis cardiomyopathy
Diagnosis of TTR amyloidosis cardiomyopathy with scintigraphy
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Males and Females.
* Age ≥50 years.
* Left ventricular hypertrophy (LVH) defined as end-diastolic LV maximum wall thickness (MWT) ≥15mm in Echocardiogram.
* Plan to undergo or recently underwent radionuclide bone scintigraphy and/or SPECT with any of the following radio labelled tracers: 99mTc-DPD or 99mTc-PYP or 99mTc-HMDP.
Exclusion Criteria
* Severe aortic stenosis defined as aortic valve area (AVA) \< 1.0 cm2
50 Years
99 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The Prince Charles Hospital
Chermside, , Australia
The Alfred Department of Cardiology
Melbourne, , Australia
Medizinische Universität Innsbruck - Universitätsklinik für Innere Medizin III, Kardiologie
Innsbruck, , Austria
Centre Hospitalier Universitaire de Caen
Caen, Cedex, France
Hopital Henri Mondor, Service de Pharmacologie Clinique
Créteil, , France
CHU de Nantes
Nantes, , France
CHU de Toulouse
Toulouse, , France
Divisione di Cardiologia
Bologna, , Italy
Careggi Hospital
Florence, , Italy
Centro Hospitalar e Universitario de Coimbra
Coimbra, , Portugal
Centro Hospitalar de Lisboa Central, E.P.E.
Lisbon, , Portugal
Fundeni Clinical Institute
Bucharest, , Romania
Inherited Cardiovascular Diseases - Cardiology Institute
Bucharest, , Romania
East Slovak Institute of Cardiovascular Diseases
Košice, , Slovakia
University Medical Centre Ljubljana - Department of Cardiology
Ljubljana, , Slovenia
Cardiomyopathy Unit, Department of Cardiology
Majadahonda, Madrid, Spain
Hospital Universitario A Coruna
A Coruña, , Spain
The Heart Hospital - University College London Hospitals Nhs Foundation Trust
London, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Garcia-Pavia P, Del Moral FJH, Cappelli F, Piriou N, Barriales-Villa R, Munteanu C, Bahus C, Keohane D, Mallaina P, Itti E, Damy T, Elliott P. Nuclear imaging and echocardiographic findings in hypertrophic cardiomyopathy with and without ATTR-CM. ESC Heart Fail. 2025 Oct 13. doi: 10.1002/ehf2.15440. Online ahead of print.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TTRACK
Identifier Type: OTHER
Identifier Source: secondary_id
B3461058
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.